Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sorafenib–regorafenib sequential therapy in advanced hepatocellular carcinoma after lenvatinib
jRCT1041190082Phase 2Recruiting
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in hepatocellular carcinoma (HCC). Primary endpoint: 1-year survival rate. Started Dec 2019; status: recruiting.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT1041190082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041190082.